REFERENCES
- Collins SJ. Acute promyelocytic leukemia: relieving repression induces remission. Blood. 1998; 91: 2631–2633.
- Soignet S, Fleischauer A, Polyak T, Heller G, Warrell RP. All-trans retinoic acid significantly increases 5-year survival in Patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother Pharmacol. 1997; 40 (suppl): S25-S29.
- Soignet SL, Frankel SR, Douer D, et al. United States mut-licenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001; 19: 3852–3860.
- Bernstein ID. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 2000; 14: 474–475.
- Amico D, Barbui AM, Erba E, Rambaldi A, Introna M, Golay J. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chkl and Chk2 phosphorylation and caspase 3. Blood 2003; 101: 4589-4597.
- Paietta E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J, et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute mye-loid leukemia: immunological, molecular and functional analyses. Leukemia 1994; 8: 968–973.
- Takeshita A, Shinjo K, Naito K, Matsui H, Sahara N, Shi-geno K, et al. Efficacy of gemtuzumab ozogamicin on ATRA-and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia 2005; 19: 1306–1311.
- Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fe-naux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2009; 113 (9): 1875-1891. Epub 2008 Sep 23.
- Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH, et al. Experience with gemtuzumab ozogamycin (“mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leu-kemia. Blood 2002; 99: 4222–4224.
- Breccia M, Cimino G, Diverio D, Gentilini F, MandeIli F, Lo Coco F. Sustained molecular remission after low dose gem-tuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. Haematologica. 2007; 92 (9): 1273–1274.
- Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004; 104 (7): 1995-1999. Epub 2004 Jun 8
- Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, et al. Combination therapy with arsenic tri-oxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer. 2007; 109 (7): 1355–9.